AMLX amylyx.com: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The efficiency of Amylyx Pharmaceuticals (AMLX) is based on the commercialization of ALS drugs. The business valuation based on EV/EBITDA clearly demonstrates the value dynamics, where the parameter value equals 0.00. The foundation is built by elite neurobiologists motivated by options and a mission, as well as colossal unmet demand in the market for severe nervous system pathology therapies, which opens broad scaling prospects.
Comprehensive metric breakdowns and analytics for amylyx.com (AMLX)
- stock price and consensus target price:
- company stock capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Amylyx Pharmaceuticals, Inc.|AMLX - Company Aggregate Indebtedness|Debts to Book Capitalization Amylyx Corp|AMLX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Amylyx Pharmaceuticals|Quick Liquidity amylyx.com
- net income and valuation multiples indicators:
AMLX - Final Profit|Expected Profit Amylyx Pharmaceuticals|AMLX - Price to Earnings Ratio|Forward P/E Multiple Amylyx Pharmaceuticals|AMLX - PEG Multiple|EV/EBITDA Multiple Amylyx Corp|AMLX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Amylyx Pharmaceuticals|AMLX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months amylyx.com|AMLX - Earnings growth in current year|Expected earnings per share growth for next year Amylyx Pharmaceuticals
Fundamental valuation:Amylyx AMLX
For Amylyx Pharmaceuticals (AMLX), which implements robotic neuron screening to accelerate R&D, this indicator is critical when assessing capital-intensive development stages. The metric relates the total enterprise value (equity plus net debt) to EBITDA, determining the business payback period excluding tax effects. Analyzing the EV/EBITDA ratio on the value chart allows investors to promptly track asset revaluation relative to the company's actual efficiency.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AXSM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to EBITDA Ratio VKTX|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN (Biohaven Ltd) - Company Value to Operating Income Before Depreciation Ratio|Trevi Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|AVXL: EV/EBITDA Multiple|ceribell.com (CBLL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Corporation plc|ALEC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Inc. (ANNX)|Enterprise Value to EBITDA Ratio omeros.com OMER|EV/EBITDA Multiple NGNE (Neurogene Inc.)|EV/EBITDA Multiple acimmune.com ACIU|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|Company Value to EBITDA Tevogen Bio Inc. (TVGN)|Enterprise Value to EBITDA Ratio ACOG|EV/EBITDA Multiple cogrx.com|Enterprise Value to EBITDA Ratio IKT (Inhibikase Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SAVA|EV/EBITDA Multiple ASRT (Assertio)|Total Company Value to Operating Income Before Depreciation Ratio Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Ovid Therapeutics Inc. (OVID) - Enterprise Value to EBITDA Ratio|ABOS: EV/EBITDA Multiple|CervoMed, Inc. (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|EV/EBITDA Multiple Annovis Bio Inc ANVS|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Firefly Neuro (AIFF) - Enterprise Value to EBITDA Ratio|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NRSN (NeuroSense Therapeutics Ltd.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio RVPH|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV: Enterprise Value to EBITDA Ratio|ATHA - EV/EBITDA Multiple|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Company Value to EBITDA Protagenic PTIX|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI - Enterprise Value to EBITDA Ratio|CARA: Enterprise Value to EBITDA Ratio|Company Value to EBITDA chromocell.com|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITCI (Intra-Cellular Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio LBPH|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|neurobopharma.com - Enterprise Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|cerevel.com - Business Value to Operating Income Before Depreciation
